Rheumatoid Arthritis Clinical Trials

Anniston : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Anniston : Investigational Site Number 840070

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Birmingham : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Birmingham : 209

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Birmingham : 209

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Birmingham : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Birmingham : 141

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Huntsville : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Huntsville :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Huntsville : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Huntsville : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Huntsville : 170

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Huntsville : 170

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Huntsville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Huntsville : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Mobile : 180

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Mobile : 180

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Tuscaloosa :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Tuscaloosa : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Tuscaloosa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tuscaloosa : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Tuscaloosa : 214

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Scottsdale : Radiant Research - Scottsdale

Rheumatoid Arthritis (RA) Research Study

View More »

Gilbert :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Gilbert : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Glendale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Glendale : 247

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Glendale : 247

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Glendale : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Glendale : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Glendale : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mesa : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Mesa : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Mesa : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Mesa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mesa : Site Reference ID/Investigator# 92113

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Paradise Valley : 165

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Paradise Valley : 234

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Paradise Valley : 234

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Paradise Valley : 165

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Paradise Valley : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Peoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Peoria : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Peoria : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Peoria : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Phoenix : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Phoenix : 187

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Phoenix : 243

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Phoenix : 187

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Phoenix : 243

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Phoenix : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Phoenix : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Phoenix : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Scottsdale : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Scottsdale : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Scottsdale : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Scottsdale : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Tucson :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tucson : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Tucson : 251

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Tucson : 251

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Tucson : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tucson : 159

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Tucson : Investigational Site Number 840113

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Jonesboro : NEA Baptist Clinic - Clinical Research Center

If you have RA and have had an inadequate response to a TNF-a inhibitor, contact us today!

View More »

Hot Springs : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Hot Springs : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hot Springs : 152

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Little Rock : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

San Gabriel : California Center for Clinical Research

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Effectiveness of Study Drug in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Injection/Infusion Medications.

San Luis Obispo : Coastal Medical Research Group, Inc.

Have you been diagnosed with Oseoarthritis or Rheumatoid Arthritis?

View More »

Covina :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Covina : 160

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Covina : 160

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Covina : 147

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Encino : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Fresno : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Fullerton : 161

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Glendale : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Hemet : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Hemet : 257

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hemet : 257

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hemet : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Hemet : Site Reference ID/Investigator# 92118

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Huntington Beach : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Huntington Beach : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Huntington Beach : 164

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Huntington Beach : 164

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Huntington Beach : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Huntington Beach : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Inglewood : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

La Jolla : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

La Jolla : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

La Jolla : Scripps Clinic

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

La Mesa : Call for Information (Investigational Site 0011)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

La Mesa : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

La Mesa : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

La Mesa : 217

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Lakewood : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Long Beach : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Long Beach :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Long Beach : Valerius Medical Group

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Long Beach : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Long Beach : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Long Beach : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Los Alamitos : Trial Concierge/Pacific Clinical Studies

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Los Angeles :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Los Angeles : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Los Angeles : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Los Angeles : 159

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Los Angeles : 159

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Los Angeles : UCLA Semel Institute

Milnacipran for Treatment of Pain in Older Adults With Rheumatoid Arthritis

Los Angeles : 149

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Menifee : 144

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Murrieta : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Palm Desert : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Palm Desert :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Palm Desert : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Palm Desert : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Palm Desert : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Palo Alto : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Palo Alto : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Pasadena : Call for Information (Investigational Site 0006)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Pasadena :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Placentia : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Placentia : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Rancho Mirage : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Roseville : 185

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

San Diego : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

San Diego : University of California, San Diego

OTIS Autoimmune Diseases in Pregnancy Project

San Francisco : University of California, San Francisco

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

San Gabriel : Call for Information (Investigational Site 0007)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

San Leandro : 201

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Leandro : 201

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Leandro : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Santa Barbara : Investigational Site Number 840101

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Santa Maria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Santa Maria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Santa Maria : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Santa Maria : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Santa Maria : Investigational Site Number 840021

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Santa Monica : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Santa Monica : Orrin M. Troum, MD and Medical Associates

Exploratory Trial to Evaluate Premature Endothelial Dysfunction in Early Rheumatoid Arthritis(RA)Compared to Patients With Established RA, and Normal Subjects

Santa Monica : Orrin M. Troum, MD and Medical Associates

Impact of Subcutaneous Abatacept in Rheumatoid Arthritis Assessing Inhibition of Structural Damage

Torrance : Novatis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Torrance : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tustin : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Tustin : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Upland :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Upland : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Upland : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Upland : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Upland : 202

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Upland : 202

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Upland : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Upland : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Upland : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Upland : Investigational Site Number 840049

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Van Nuys :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Van Nuys : 189

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Victorville : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Whittier :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Whittier : 172

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Whittier : 172

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Whittier : 148

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Boulder : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Colorado Springs : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Colorado Springs : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Denver :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

View More »

Denver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Denver : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Denver : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Fort Collins : Orthopedic Center of the Rockies

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Longmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Longmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Longmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Longmont : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Stamford : Stamford Therapeutics Consortium

Rheumatoid Arthritis pain?

View More »

Bridgeport :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Bridgeport : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Bridgeport : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Danbury : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Danbury : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Trumbull : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Trumbull : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Trumbull : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Trumbull : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Trumbull : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Trumbull : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Lewes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Lewes : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

View More »

Newark : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Aventura : South Florida Medical Research

Phase IV, Double-Blind, Parallel-Group Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen.

Aventura : South Florida Medical Research

Study of patients with Osteoarthritis and Rheumatoid Arthritis with a high risk of cardiovascular disease comparing the efficacy and safety of a study medication with other study medications.

Clearwater : Clinical Research of West Florida

Bothered by Arthritis? Concerned About Heart Disease?

Fort Myers : Clinical Physiology Associates

Osteoarthritis or Rheumatoid Arthritis Patients

Miami : Pharmax Research Clinic, Inc.

Rheumatoid Arthritis

Tampa : Clinical Research of West Florida, Inc.

Bothered by Arthritis? Concerned About Heart Disease?

West Palm Beach : Palm Beach Research Center

Bothered by Arthritis? Concerned about Heart Disease?

View More »

Aventura : Arthritis & Rheumatic Disease Specialties Research

Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients

Aventura : 142

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Boca Raton : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Boca Raton : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Boca Raton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Boynton Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Brandon : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Coral Springs : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Daytona Beach : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Daytona Beach : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Daytona Beach : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Daytona Beach : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Edgewater : Riverside Clinical Research

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Fort Lauderdale : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Fort Lauderdale : 190

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Fort Lauderdale : 190

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Gainesville : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Gainesville : University of Florida

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Gainesville : 162

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Jacksonville : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Jacksonville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Jacksonville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Jacksonville : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Jupiter : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Jupiter : 196

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Jupiter : 196

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Lake Mary :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Lake Mary : 238

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Lake Mary : 238

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Miami :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Miami : Global Clinical Professionals

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Miami : 232

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Miami : 232

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Miami : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Miami : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Miami : Investigational Site Number 840048

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Naples : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Naples : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Naples : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Naples : 213

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Naples : 213

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Naples : Investigational Site Number 840024

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

New Port Richey : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

New Port Richey : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

North Miami Beach : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Ocala : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Ocala :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Ocala :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Ocala : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Ocala : 214

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Ocala : 214

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Ocala : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Ocala : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ocala : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Orange Park : 237

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orange Park : 237

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orlando :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Orlando : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Orlando : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Orlando : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Orlando : 255

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orlando : 255

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orlando : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ormond Beach : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Palm Harbor :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Palm Harbor :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Palm Harbor : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Palm Harbor : The Arthritis Center

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Palm Harbor : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Palm Harbor : 163

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Palm Harbor : 163

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Palm Harbor : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Palm Harbor : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Palm Harbor : Investigational Site Number 840063

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Pinellas Park : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Pinellas Park : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Plantation : 166

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Plantation : 166

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Sarasota : 192

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Sarasota : 192

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Sarasota : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

South Miami :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

South Miami : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Summerfield : Lakeview Medical Research

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Tamarac : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tampa : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Tampa :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Tampa : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Tampa :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Tampa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Tampa : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Tampa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tampa : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Tampa Bay : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Tavares :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Venice : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Venice : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Venice : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Vero Beach : 200

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Vero Beach : 200

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Vero Beach : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Vero Beach : 209

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

West Palm Beach : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Zephyr Hills : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Zephyrhills : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Alpharetta : CSI Research Inc

(OSKIRA): A Phase III, Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study of Two Dosing Regimens of Investigational Product (Oral Agents) in Rheumatoid Arthritis Patients.

Alpharetta : CSI Research Inc

A Phase 2, 12-week, double-blind, randomized, parallel group, placebo-controlled study of four doses of Study Medication in subjects with moderate to severe rheumatoid arthritis

Alpharetta : CSI Research Inc

A Phase 3 Study Comparing 2 Doses of study drug vs. Placebo for Treatment of Rheumatoid Arthritis

Alpharetta : CSI Research Inc

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Investigational Product in Patients With Rheumatoid Arthritis (RA) With or Without Background Disease-Modifying Anti-rheumatic Drug (DMARD) Therapy

Marietta : Georgia Institute for Clinical Research, LLC

A Multicenter, 12 Week, Randomized, Double-blind, Placebo-controlled Biomarker Study of Secukinumab (AIN457) in Rheumatoid Arthritis Patients Followed by an Open Label Extension

Woodstock : North Georgia Clinical Research

Bothered by Arthritis? Concerned about Heart Disease?

View More »

Atlanta : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Atlanta : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Canton : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Canton : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Canton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Decatur : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Decatur : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Gainesville : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Macon : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Meridian : Advanced Clinical Research, ID

Bothered by Arthritis? Concerned about Heart Disease?

View More »

Coeur D'alene :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Coeur D'alene : 226

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Coeur D'alene : 226

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Coeur D'alene : 145

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Idaho Falls : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Idaho Falls : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Idaho Falls : Investigational Site Number 840018

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Meridian : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Burr Ridge : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Chicago : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Maywood : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Maywood : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Morton Grove : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

View More »

Oakbrook Terrace : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Rock Island : 219

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Rock Island : 219

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Rockford : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Rockford : Rockford Orthopedics Associates

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Springfield : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Springfield : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Springfield : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Springfield : 244

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Springfield : 244

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Springfield : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Vernon Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Vernon Hills : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Bloomington : Bloomington Bone and Joint Clinic

Ascension® MCP Post-Approval Study

Fort Wayne : Parkview Health

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Granger :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

View More »

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Indianapolis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Rock Island : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Rock Island : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

South Bend : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

South Bend : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

South Bend : 224

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

South Bend : 224

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

South Bend : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

South Bend : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

South Bend : Saint Joseph Regional Medical Center

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Cedar Rapids : 215

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Cedar Rapids : 215

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wichita : Via Christi Research

CARES: Cardiovascular Safety of Febuxostat & Allopurinol in Gout & Cardiovascular Comorbidities

Wichita : Wichita Clinic, PA

Clinical Research Trial studying Rheumatoid Arthritis Therapy and Vaccines

Wichita : Wichita Clinic, PA

Have you been diagnosed with Rheumatoid Arthritis.

Wichita : Wichita Clinic, PA

Have you been diagnosed with Rheumatoid Arthritis?

Wichita : Via Christi Research

NURTURE 1: Secukinumab in Active Rheumatoid Arthritis Not Responding to Anti-TNFa Drugs

Wichita : Via Christi Research

PRECISION: Prospective Randomized Evaluation of Celecoxib Integrated Safety vs. Ibuprofen Or Naproxen

Wichita : Via Christi Research

VX-509 with Methotrexate for Rheumatoid Arthritis

View More »

Kansas City : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Kansas City : University of Kansas Medical Center

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Lenexa : Analan Clinical Research

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Wichita : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Wichita :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Wichita : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Wichita : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Wichita : 210

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wichita : 210

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wichita : 191

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wichita : 191

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wichita : Site Reference ID/Investigator# 92117

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Witchita : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Bowling Green : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Bowling Green : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Bowling Green : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Elizabethtown : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Elizabethtown : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

View More »

Elizabethtown : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Elizabethtown : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Elizabethtown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lexington : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Lexington :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Lexington : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Lexington : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Lexington : Saint Joseph East Hospital

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Lexington : 134

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Lexington : Investigational Site Number 840015

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Louisville : Norton Orthopaedic Specialists

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

Lake Charles : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Lake Charles : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Monroe :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Monroe : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Shreveport : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Cumberland : The Osteoporosis & Clinical Trials Center

A randomized, double-blind study of the effect of ocrelizumab in combination with methotrexate, compared to methotrexate alone, on the treatment response in methotrexate-naive patients with active rheumatoid arthritis.

Cumberland : The Osteoporosis & Clinical Trials Center

A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate

Towson : Spectrum Clinical Research, Inc.

Prospective Randomized Evaluation Of Celecoxib Integrated Safety Vs Ibuprofen Or Naproxen (PRECISION)

Wheaton : The Center for Rheumatology and Bone Research

A 2 arm study to evaluate Tocilizumab IV vs Enbrel SQ for 5 years

Wheaton : The Center for Rheumatology and Bone Research

A phase 2b, Study to Evaluate the Safety and Efficacy of JAK inhibitor for Moderate to Severe Rheumatoid Arthritis

Wheaton : The Center for Rheumatology and Bone Research

A randomized , double-blind, placebo-controlled , multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of IL-6Ra mAb on top of methotrexate in patients with active rheumatoid arthritis who are inadequate responders of MTX therapy.

Wheaton : The Center for Rheumatology and Bone Research

A randomized, double-blind, parallel-group study of Cardiovascular safety in Osteoarthritis or Rheumatoid Arthritis patients with or at high risk for Cardiovascular disease comparing Celecoxib with Naproxen and Ibuprofen.

Wheaton : The Center for Rheumatology and Bone Research

A Study on The Safety of Administering MabThera/Rituxan (Rituximab) at A More Rapid Rate in Patients With Rheumatoid Arthritis (RATE-RA)

Wheaton : The Center for Rheumatology and Bone Research

Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis

Wheaton : The Center for Rheumatology and Bone Research

Phase 3b Golimumab Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients who have Inadequate disease control despite treatment with Etanercept (Enbrel) or Adalimumab (Humira)

View More »

Baltimore : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Baltimore : 218

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Baltimore : 218

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Baltimore : 178

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Cumberland : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Cumberland : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Cumberland : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Cumberland : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Frederick :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Frederick : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Frederick : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Hagerstown : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Hagerstown : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Hagerstown : 177

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hagerstown : 177

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hagerstown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Oxon Hill : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Oxon Hill : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Wheaton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Wheaton : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Hyannis : Clinical Research Center of Cape Cod, Inc

Do you have Osteoarthritis or Rheumatoid Arthritis and are at High Risk for Cardiovascular Disease?

View More »

Boston : Brigham and Women's Hospital

Brigham and Women's Rheumatoid Arthritis Sequential Study

Boston : Brigham and Women's Hospital

Patient Rheumatoid Arthritis Social Support Study

Boston : Brigham and Women's Hospital

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Fall River : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Worcester : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Worcester : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Worcester : University of Massachusetts Medical School

Teriparatide for Joint Erosions in Rheumatoid Arthritis: The TERA Trial

Worchester :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Ann Arbor : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Battle Creek : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Battle Creek : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Battle Creek : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Battle Creek : 137

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

View More »

Detroit : 153

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Grand Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Grand Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Grand Rapids : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Kalamazoo : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Kalamazoo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Kalamazoo : Call for Information (Investigational Site 0005)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Kalamazoo : Call for Information (Investigational Site 0009)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Kalamazoo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Kalamazoo : 199

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Kalamazoo : 199

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Kalamazoo : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Kalamazoo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lansing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Lansing : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Lansing :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Lansing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Lansing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Lansing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Lansing : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lansing : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Lansing : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Lansing : 155

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

St. Clair Shores : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

St. Claire Shores :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Chaska : Ridgeview Research

Rheumatoid Arthritis

View More »

Chaska : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Eagan :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Eagan : 198

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Eagan : 198

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Eagan : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Eagan : 204

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Edina : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Saint Louis Park : 143

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Flowood : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Flowood : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Flowood : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tupelo : 203

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Tupelo : 203

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Columbia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Florissant :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Florissant : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lees Summit : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Richmond Heights : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

View More »

Richmond Heights : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Saint Louis : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

St Louis :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

St Louis : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

St. Louis : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

St. Louis : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

St. Louis : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

St. Louis : 179

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

St. Louis : 179

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

St. Louis : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Kalispell : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Kalispell : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Kalispell : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Lincoln : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Lincoln : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Lincoln : 181

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Lincoln : 181

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Lincoln : Investigational Site Number 840112

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

View More »

Omaha : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Omaha :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis

Omaha : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Omaha : 135

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Las Vegas : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Las Vegas : Advanced BioMedical Research of America

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Las Vegas : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Reno : Arthritis Center of Reno

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Reno : 256

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Reno : 256

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Reno : 170

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Lebanon :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Lebanon : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Lebanon : 229

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Lebanon : 229

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Nashua : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

New Brunswick : UMDNJ-Robert Wood Johnson Medical School

A multi-center, randomized, blinded, parallel-group study of the reduction of signs and symptoms during monotherapy treatment with tocilizumab 8 mg/kg intravenously versus adalimumab 40 mg subcutaneously in patients with rheumatoid arthritis

View More »

Clifton : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Clifton : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Clifton : 228

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Clifton : 228

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Clifton : Site Reference ID/Investigator# 92115

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Egg Harbor Township : Rothman Institute

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Egg Harbor Township : The Rothman Institute

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Freehold : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Freehold :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Freehold : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Freehold : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Freehold : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Freehold : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Freehold : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Freehold : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Freehold : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Manalapan :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Teaneck : 201

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Toms River : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Toms River : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Toms River : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Voorhees :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Voorhees : 150

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Albuquerque :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Albuquerque : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Albuquerque : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Albuquerque : 207

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Albuquerque : 207

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Albuquerque : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Albuquerque : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Albuquerque : 205

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Las Cruces : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Las Cruces : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mineola : Winthrop University Hospital Clinical Trials Center

Rheumatoid Arthritis

New York : The Rockefeller University Hospital

Evaluation of Immune Activation in Rheumatoid Arthritis

Rochester : Rochester Clinical Research

Rheumatoid Arthritis

View More »

Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Albany : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Albany : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Albany : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Albany : 154

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Brooklyn : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Brooklyn : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Brooklyn : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Brooklyn : 176

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brooklyn : 176

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brooklyn : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Brooklyn : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Brooklyn : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Brooklyn : 136

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Hartsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Hartsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Hartsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Hartsdale : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Lake Success : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

New York :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

New York City : Kenneth Mroczek, MD-NYU

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Olean : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Orchard Park :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Orchard Park : Investigational Site Number 840106

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Plainview : 242

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Plainview : 242

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Plainview : 207

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rochester : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Rochester : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Rochester : 227

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Rochester : 227

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Roslyn : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Roslyn : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Roslyn : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Roslyn : Investigational Site Number 840115

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Smithtown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Syracuse : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Syracuse : 167

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Charlotte : PMG Research of Charlotte

ARTHRITIS AND HEART DISEASE: Research Study

Hickory : PMG Research of Hickory

Are your joints painful and swollen from Rheumatoid Arthritis (RA)?

Hickory : PMG Research of Hickory

ARTHRITIS AND HEART DISEASE: Research Study

Hickory : PMG Research of Hickory

Do you suffer from moderated to severe rheumatoid arthritis?

Hickory : PMG Research of Hickory

Do you suffer from Rheumatoid Arthritis?

Hickory : PMG Research of Hickory

Have you been taking Methotrexate for at least 3 months for your Rheumatoid Arthritis?

Raleigh : PMG Research of Raleigh

ARTHRITIS AND HEART DISEASE: Research Study

Salisbury : PMG Research of Salisbury

ARTHRITIS AND HEART DISEASE: Research Study

Salisbury : PMG Research of Salisbury

Do you Have Rheumatoid Arthritis?

Wilmington : PMG Research of Wilmington

ARTHRITIS AND HEART DISEASE: Research Study

Winston-Salem : PMG Research of Winston-Salem

ARTHRITIS AND HEART DISEASE: Research Study

View More »

Asheville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Asheville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Asheville : Mission Health System

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Chapel Hill : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Charlotte : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Charlotte :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Charlotte : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Charlotte : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Charlotte : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Charlotte : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Charlotte : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Charlotte : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Charlotte : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Durham : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Durham : 236

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Durham : 236

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Durham : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Durham : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Greenboro : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Greensboro : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Greensboro : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hickory : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Hickory : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Hickory : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Hickory : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Raleigh :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Raleigh :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Raleigh : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Rocky Mount : 246

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Rocky Mount : 246

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Salisbury : PMG Research of Salisbury

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Wilmington :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Wilmington : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Bismarck : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Minot : 182

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Minot : 182

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Akron : Radiant Research - Akron

Rheumatoid Arthritis Research Study

Cleveland : Rapid Medical Research, Inc. (RMR)

Do you suffer from arthritis pain?

Dayton : Providence Health Partners - Center for Clinical Research

Rheumatoid Arthritis

View More »

Akron : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Cincinnati :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Cincinnati : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Cincinnati : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Cincinnati : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Cincinnati : 140

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Columbus : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Dayton : Providence Health Partners

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Dayton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Gallipolis : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kettering : Kettering Health Network

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Mayfield Village : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mayfield Village : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Middleburg Heights : Paramount Medical Research & Consulting, LLC

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Middleburg Heights : 245

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Middleburg Heights : 245

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Perrysburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Perrysburg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Perrysburg : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Perrysburg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Toledo : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Oklahoma City : Bone and Joint Hospital at St. Anthony

Rheumatoid Arthritis Research Study

Oklahoma City : Bone and Joint Hospital at St. Anthony

Rheumatoid Arthritis
The Flex-V Study

View More »

Norman : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Norman : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Oklahoma City : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Oklahoma City :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Oklahoma City : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Oklahoma City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Oklahoma City : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Oklahoma City : 241

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Oklahoma City : 241

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Oklahoma City : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Oklahoma City : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Oklahoma City : 184

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Oklahoma City : Novartis Investigative Site

Study to Evaluate the Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Rheumatoid Arthritis

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Tulsa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Bend : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Bend : The Center

Ascension® MCP Post-Approval Study

Lake Oswego : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Lake Oswego : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Portland : 186

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Portland : 186

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Portland : Novatis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Portland : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Bethlehem : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Bethlehem :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Bethlehem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

View More »

Bethlehem : 195

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bethlehem : 195

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bethlehem : 164

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Ducansville : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Duncansville : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Duncansville : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Duncansville : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Duncansville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Duncansville : Research Site

Effects of Denosumab on the Pharmacokinetics of Etanercept

Duncansville : 167

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Duncansville : 167

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Duncansville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Duncansville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Duncansville : Pfizer Investigational Site

Rheumatoid Arthritis Extension Trial For Subjects Who Have Participated In Other PF-05280586 Trials (REFLECTIONS B328-04)

Duncansville : 132

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Duncansville : Investigational Site Number 840009

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Erie : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Erie : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Hershey : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Philadelphia : University of Pennsylvania Health Systems-PA Foot and Ankle Surgeons

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Philadelphia : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Philadelphia : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Philadelphia : Rothman Institute

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Philadelphia : The Rothman Institute

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Philadelphia : Site Reference ID/Investigator# 92116

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Philadephia : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Pittsburgh : University of Pittsburgh - Oakland Falk Clinic

Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants

Reading : Investigational Site Number 840062

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Waxford : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

West Reading : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Willow Grove : 220

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Willow Grove : 220

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wyomissing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Wyomissing : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Wyomissing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Wyomissing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Wyomissing : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Wyomissing : 168

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wyomissing : 168

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wyomissing : 190

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Greer : Radiant Research - Greer

Rheumatoid Arthritis Research

View More »

Charleston :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Charleston :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Charleston : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Charleston : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Charleston : 189

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Charleston : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Charleston : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Charleston : Site Reference ID/Investigator# 92114

Study in Rheumatoid Arthritis for Subjects Who Completed Preceding Study M13-390 With Adalimumab

Charleston : 210

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Columbia : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Columbia : 205

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Columbia : 205

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Florence :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Greenville : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Greenville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Greenville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Greer : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Myrtle Beach : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Myrtle Beach : 187

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

North Charleston : 189

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orangeburg : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Orangeburg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Orangeburg : 203

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Rapid City : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Bristol : PMG Research of Bristol

ARTHRITIS AND HEART DISEASE: Research Study

View More »

Hendersonville : 204

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hendersonville : 204

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hixson : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Jackson : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Jackson : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Jackson : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Jackson : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Jackson : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Jackson : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Jackson : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Jackson : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Jackson : 133

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Jackson : Investigational Site Number 840025

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Johnson City : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Kingsport : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Knoxville : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Knoxville : 160

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Memphis :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Memphis : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Memphis : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Memphis : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Memphis : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Nashville : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Nashville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Dallas : Metroplex Clinical Research Center

A clinical trial testing the efficacy and safety of an investigational medication for people with moderately to severely active rheumatoid arthritis

Dallas : Metroplex Clinical Research Center

A randomized, double-blind, active-controlled, phase 3 study to evaluate the efficacy and safety of an investigational drug in patients with moderately to severely active rheumatoid arthritis who have had limited or no treatment with disease-modifying antirheumatic drugs

Dallas : Metroplex Clinical Research Center

A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders or intolerant to TNF alpha-antagonists

Dallas : Metroplex Clinical Research Center

A randomized, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of an investigational drug in patients with inadequate response to conventional disease-modifying antirheumatic drugs with moderately to severely active rheumatoid arthritis

Dallas : Metroplex Clinical Research Center

Do You Have Early Active Rheumatoid Arthritis? Research Study RA0055

Dallas : Metroplex Clinical Research Center

Do You Have Moderate to Severe Rheumatoid Arthritis? Research Study RA0077

Dallas : Metroplex Clinical Research Center

Do You Have Rheumatoid Arthritis? Research Study 2409

Dallas : Metroplex Clinical Research Center

Do You Have Rheumatoid Arthritis? Research Study ENTRACTE

Dallas : Metroplex Clinical Research Center

Do You Have Rheumatoid Arthritis? Osteoporosis or Osteopenia? Research Study 20101324

Dallas : Metroplex Clinical Research Center

Do You Have Rheumatoid Arthritis? Research Study B3281001

Houston : DM Clinical Research

Rheumatoid Arthritis

View More »

Allen : 217

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Allen : 217

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Amarillo : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Amarillo : 185

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Amarillo : 185

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Amarillo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Austin : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Austin :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Austin : Site Reference ID/Investigator# 92153

A Study in Healthy Adults and Adult Subjects With Rheumatoid Arthritis to Evaluate the Safety, Tolerability and Pharmacokinetics After Multiple Doses of ABT-494

Austin : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Austin : 161

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Austin : 161

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Austin : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Austin : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Austin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Austin : 138

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Benbrook : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Corpus Christi : 178

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Corpus Christi : 151

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Corpus Christy : 178

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Dallas : Charles E. Cook, MD

2-Year Post-Approval Study to Investigate the Scandinavian Total Ankle Replacement System (STAR) Ankle Under Actual Conditions of Use

Dallas : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Dallas : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Dallas : Research Site

Effects of Denosumab on the Pharmacokinetics of Etanercept

Dallas : 162

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Dallas : 162

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Dallas : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Dallas : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Dallas : 131

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Dallas : 146

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Dallas : Investigational Site Number 840022

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Houston : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Houston :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Houston : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Houston : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Houston : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Houston : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Houston : Fondren Orthopedic Group

Ascension® MCP Post-Approval Study

Houston : 184

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Houston : 206

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Houston : 184

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Houston : 223

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Houston : 206

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Houston : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Houston : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Houston : Texas Orthopedic Hospital

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Houston : 166

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Houston : 212

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Lubbock : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Lubbock : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

McKinney : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Mesquite : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Mesquite : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Mesquite : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Mesquite : 158

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Mesquite : 158

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Mesquite : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Mesquite : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Mesquite : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mesquite : Investigational Site Number 840074

To Evaluate The Effect Of SAR153191 (REGN88) Added To Other RA Drugs In Patients With RA Who Are Not Responding To Or Intolerant Of Anti-TNF Therapy (SARIL-RA-TARGET)

Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Nassau Bay : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Nassau Bay : 175

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Nassau Bay : 175

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Nassau Bay : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Plano : 249

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Plano : 249

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Antonio : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

San Antonio : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

San Antonio : 197

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Antonio : 197

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Antonio : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

San Antonio : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Antonio : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

San Antonio : 139

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sugar Land : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Sugar Land : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Sugar Land : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Sugar Land : 223

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Sugar Land : 181

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Victoria : 165

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Waco : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Webster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Webster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Webster : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

West Jordan : Advanced Clinical Research, UT

There's a new clinical study for people who have arthritis and are also at risk for heart disease.

View More »

Salt Lake City : Novartis Investigative Site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Arlington : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Arlington : 211

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

View More »

Chesapeake : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Chesapeake : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chesapeake : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Williamsburg : The Center for Excellence in Aging and Geriatric Health

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Kennewick : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Kennewick : 233

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Kennewick : 233

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Olympia :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Olympia : South Puget Sound Clinical Research Center

A Study of Two Doses of MRC375 in Moderate to Severe Rheumatoid Arthritis Patients

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Seattle : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Seattle :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Seattle : University of Washington Medical Center

Safety and Effectiveness Study of Ascension's PyroCarbon Radial Head Compared to Ascension's Metal Radial Head

Spokane : Vertex Investigational Site

A Magnetic Resonance Imaging Study and Arthroscopic Biopsy Substudy in Subjects With Active Rheumatoid Arthritis Receiving VX-509, an Oral JAK3 Inhibitor

Spokane :

A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of INCB039110 in Subjects With Active Rheumatoid Arthritis

Spokane : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Spokane : 157

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tacoma : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Tacoma : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Tacoma : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Vancouver : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Wenatchee :

A Long-Term Extension Study of WA22762 and NA25220 of RoActemra/Actemra (Tocilizumab) Administered Subcutaneously in Patients With Moderate to Severe Rheumatoid Arthritis

Beckley : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Beckley : Novo Nordisk Clinical Trial Call Center

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Clarksburg : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Clarksburg : 183

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Clarksburg : 183

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Clarksburg : 163

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Franklin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Franklin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Franklin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Franklin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Glendale : 174

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Glendale : 174

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Glendale : 215

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Milwaukee : Medical College of Wisconsin

Ankle Joint Replacement Outcomes Study

Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Racine : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Buenos Aires : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Buenos Aires :

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

View More »

Buenos Aires : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Buenos Aires :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Buenos Aires :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Buenos Aires : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Buenos Aires : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Caba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Caba : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Capital Federal : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Ciudad Autonoma Bs As : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ciudad Autonoma de :

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Cordoba : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

La Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Mar Del Plata : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Mendoza :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Quilmes :

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Quilmes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Quilmes : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Rosario : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Rosario : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Juan :

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

San Juan : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

San Juan : 279

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Juan : 279

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

San Juan : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

San Miguel de Tucman :

A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

San Miguel de Tucuman : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Santa Fe : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tucuman : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Tucuman : 291

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Tucuman : 291

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Tucuman : Local Institution

Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis

Adelaide : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

Cairns : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Cairns : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Camperdown : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Camperdown : 6

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

View More »

Campsie : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

Campsie, Sydney : Site Reference ID/Investigator# 55262

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Clayton : 7

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Coffs Harbour : 6

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Coffs Harbour : 6

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Coffs Harbour : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

Coffs Harbour : Site Reference ID/Investigator# 56428

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Fitzroy : 5

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Fitzroy : 5

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Fitzroy : Site Reference ID/Investigator# 55263

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Fitzroy : 8

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Fitzroy VIC : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Garran : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Garran : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Geelong : 4

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Geelong : 4

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Geelong : Site Reference ID/Investigator# 56427

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Heidelberg : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Heidelberg : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

Herson : 2

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Herson : 2

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hobart : 4

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Kogarah : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Kogarah : 5

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Malvern : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Malvern : 3

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Malvern : 3

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Malvern : 1

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Malvern East : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Maroochydore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Maroochydore : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Maroochydore : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Maroochydore : 1

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Maroochydore : 1

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Maroochydore : 2

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Moroochydore : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Morwell : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

New Lambton : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

Perth : 7

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Perth : 7

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Shenton Park : Updated

Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis in Australia

Shenton Park : Site Reference ID/Investigator# 56426

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

South Granville : Merck Sharp & Dohme/Australia

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Southport : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Subiaco : 3

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Victoria Park : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Woodville : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Woodville South : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Woodville South : 8

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Woodville South : 8

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Graz : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Graz :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Graz-eggenberg :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Hollabrunn :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Innsbruck :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

View More »

Linz :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Salzburg :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Stockerau : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Stockerau :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Stockerau : 85

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Vienna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Vienna : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Wels :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Wien :

A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate

Wien : 50

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wien : 50

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Wien : 22

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Minsk : Merck Sharp & Dohme IDEA, Inc.

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM4 EXT 1)

Aalst :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Aalst :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Aalst : Site Reference ID/Investigator# 59366

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Aalst : Site Reference ID/Investigator# 56989

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

ATH :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

View More »

AYE :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bruges : Site Reference ID/Investigator# 56984

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Brugge : Algemeen Ziekenhuis Sint Jan

Correlation Between Beliefs About Medicine and Objective Measures of Efficacy and Safety in Rheumatoid Arthritis (RA)

Brussels : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Brussels : 51

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brussels : 51

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brussels : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Brussels : Site Reference ID/Investigator# 57011

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Brussels : Site Reference ID/Investigator# 57020

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Bruxelles :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Bruxelles :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Bruxelles :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bruxelles : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Ceroux-Mousty : Site Reference ID/Investigator# 57019

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Champion : Site Reference ID/Investigator# 57023

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Edegem :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Edegem :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Erembodegem : Site Reference ID/Investigator# 56988

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Genk :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Genk :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Genk :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Genk : Site Reference ID/Investigator# 56990

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Genk : Site Reference ID/Investigator# 57004

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Gent :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Gent : 31

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Gent : 31

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Ghent : Ghent University Hospital

Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFα in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis

Gilly :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Gilly :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Gilly : 126

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Gilly : 126

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Gistel : Site Reference ID/Investigator# 56987

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Godinne :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Gosselies :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Haine-saint-paul :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Heist-op-den-Berg : Site Reference ID/Investigator# 60302

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Heusy :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Heusy :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Ixelles :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Kortrijk :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Kortrijk : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Kortrijk : 36

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Kortrijk : 36

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

La Louviere : Site Reference ID/Investigator# 57010

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Leuven : 30

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Leuven : 30

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Liege :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Liege :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Liege :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Liege : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Liège :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Liège :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Mechelen : Site Reference ID/Investigator# 57006

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Merksem : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Merksem : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Mons :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Mons : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Mons : Site Reference ID/Investigator# 57014

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Nalinnes : Site Reference ID/Investigator# 57008

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Oostende :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Oostende :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Ottignies :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Oudenaarde : Site Reference ID/Investigator# 56991

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Roeselare :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Roeselare : Site Reference ID/Investigator# 59022

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Sint-Niklaas : Site Reference ID/Investigator# 57003

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Sint-Niklaas : Site Reference ID/Investigator# 56992

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Turnhout :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Verviers :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Waterloo : Site Reference ID/Investigator# 57007

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Westmalle :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Wilrijk :

A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy

Wilrijk :

A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE)

Wilrijk : Site Reference ID/Investigator# 56985

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Yvoir :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Yvoir : 65

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Yvoir : 65

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Yvoir : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mostar : Sveučilišna klinička bolnica Mostar

Long Term Extension Study For SPM-005 Participants

Mostar : Sveučilišna klinička bolnica Mostar

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Sarajevo : Klinicki Centar Univerziteta, Reumatologija

Long Term Extension Study For SPM-005 Participants

Sarajevo : Klinicki Centar Univerziteta, Reumatologija

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Curitiba : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Goiania : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Recife : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Rio de Janeiro : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

São José Do Rio Preto : Updated

A Long-term Safety Extension Study in Patients With Rheumatoid Arthritis Having Completed the Studies ML21530 And MA21488

View More »

Sao Paulo : Updated

A Long-term Safety Extension Study in Patients With Rheumatoid Arthritis Having Completed the Studies ML21530 And MA21488

Sao Paulo :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Sao Paulo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

São Paulo : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

São Paulo :

A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis

Vila Clementino :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Pleven : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Pleven : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Pleven : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Pleven : 18

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Plovdiv : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

View More »

Plovdiv : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Plovdiv : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Plovdiv : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Plovdiv : 35

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sevlievo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Sofia : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Sofia : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Sofia : Merck Sharp & Dohme Bulgaria EOOD

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM4 EXT 1)

Sofia : Nycomed Investigational Site

A Trial to Evaluate the Safety and Tolerability of MT203 in Patients With Mild to Moderate Rheumatoid Arthritis

Sofia : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Sofia : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Sofia : 46

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sofia : 21

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sofia : 29

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sofia : 34

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Stara Zagora :

A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Assess Clinical Efficacy of NNC0114-0006 in Subjects With Active Rheumatoid Arthritis

Veliko Tarnovo : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Veliko Tarnovo : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bowmanville :

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Bowmanville : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Brampton :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Brampton : Dr.'s Nalin and Vandana Ahluwalia Medicine Professional Corp.

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Brockville : Brockville Medical Centre

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

View More »

Burlington :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Burlington : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Calgary : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Edmonton :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Edmonton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Edmonton : 179

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Guelph : St. Joseph's Health Care

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Hamilton :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Hamilton : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Hamilton : 235

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hamilton : 235

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hamilton : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hamilton : 172

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Hamilton : 174

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Kamloops : Isis Investigational site

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Kelowna :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Kelowna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Kelowna : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Kelowna : 240

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Kelowna : 240

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Kitchener : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Kitchener : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Kitchener : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Laval :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Laval : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Lunenburg :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Markham :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Mississauga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Mississauga :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Mississauga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Mississauga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Mississauga : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Mississauga : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Mississauga : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Montreal :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Montreal : Institut de Rhumatologie de Montréal

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Montreal : 188

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Montreal : 188

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Montreal : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Montreal : Isis Investigational Site

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Nanaimo :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Newmarket :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Newmarket :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Ottawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Ottawa : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Ottawa : 206

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Ottawa : 177

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Penticton :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Pointe-claire :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Pointe-Claire : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Pointe-Claire : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Quebec : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Quebec : G.R.M.O. (Groupe de recherche en maladies oseuses) Inc.

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Quebec : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Quebec : 171

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Quebec City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Quebec City :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Quebec City : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Quispamsis : Eric N. Grant Professional Corp.

Cimzia Treatment in Rheumatoid Arthritis: Randomizing to Stop Versus Continue Disease-modifying Anti-rheumatic Drug(s)

Rimouski :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Rimouski : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Rimouski : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Rimouski : 218

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Sainte Foy : 169

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Saskatoon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Saskatoon :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Saskatoon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Saskatoon : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Saskatoon :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Sherbrooke :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

St John's :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

St John's : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

St. Catharines :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

St. Catharines : 175

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

St. Catherines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

St. Catherines : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

St. John's : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

St. John's : 168

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

St-eustache :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Sydney :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Toronto :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Toronto : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Toronto : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Toronto : Isis Investigational Site

Safety, Tolerability, and Pharmacodynamic Study of ISIS CRP Rx in Rheumatoid Arthritis

Trois-Rivieres : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Trois-Rivieres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Trois-Rivieres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Trois-Rivieres : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Trois-rivieres : 194

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Trois-rivieres : 194

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Trois-rivieres : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Trois-rivières :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Vancouver :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Vancouver : University of British Columbia Hospital, Vancouver

Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty

Vancouver : University of British Columbia Hospital, Vancouver

Outcomes Study of the TM Reverse Shoulder System Used in Primary or Revision Reverse Total Shoulder Arthroplasty

Victoria :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Victoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Victoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Victoria : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Windsor :

A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Moderate to Severe Rheumatoid Arthritis Study

Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis Participants

Winnipeg : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Participants With Moderate to Severe Rheumatoid Arthritis

Winnipeg :

Assess Structural Damage in Rheumatoid Arthritis Using Biomarkers and Radiography

Winnipeg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Winnipeg : Research Site

Moderate Rheumatoid Arthritis (RA) With Enbrel

Osorno : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Santiago : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Baotou : The First Affiliated Hospital of Baotou Medical College

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Baotou city : Baotou Central Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Beijing : Peking University People's Hospital

A Study of Iguratimod in Patients With Active Rheumatoid Arthritis

Beijing : Shanghai Changning Guanghua Integrative Medicine Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Changsha : The Second Xiangya Hospital of Central South University

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

View More »

Chengdu : Si Chuan Huaxi Hospital/Rheumatology Department

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Chongqing : Daping Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Fuzhou : Fujian Provincial Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Guangzhou : The First Affiliated Hospital of Guangzhou University of Chinese Medicine

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Haerbin : No. 199

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Lanzhou : Lanzhou University Second Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Nanjing : Jiangsu Province Hospital/Department of Rheumatology

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Nantong : Affiliated Hospital of Nantong University

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Shanghai : Shanghai Jiaotong University Affiliated Third People's Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Shanghai : Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis

Taiyuan : The Second Hospital of Shanxi Medical University

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Urumqi : Xinjiang Uygur Autonomous Region People's Hospital

A Study of Rheumatoid Arthritis Treatment With Enbrel in Adult Patient in Outpatient Department

Barranquilla : Pfizer Investigational Site

A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)

Barranquilla : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Barranquilla :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Barranquilla : 303

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Barranquilla : 303

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

View More »

Bogota : MDS Colombia SAS

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Bogota : MDS Colombia SAS

A Study of the Pharmacokinetics and Safety of MK-8808 (MK-8808-002 AM4 EXT 1)

Bogota :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bogota : 293

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bogota : 299

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bogota : 272

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bogota : 293

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bogota : 299

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bogota : 272

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bogota : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Bucaramanga :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bucaramanga : 297

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bucaramanga : 297

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Chia : 288

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Chia : 288

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Chía : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Medellin :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Medellin : 298

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Medellin : 298

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Medellin : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Zagreb : Sisters of Mercy Clinical Hospital Centre

Long Term Extension Study For SPM-005 Participants

Zagreb : Sisters of Mercy Clinical Hospital Centre

Safety and Efficacy Vagal Nerve Stimulation in Patients With Rheumatoid Arthritis

Brno : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Brno : 108

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brno : 108

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Brno : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Brno : Site Reference ID/Investigator# 55810

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

View More »

Brno : 103

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Bruntal : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Bruntal : 124

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bruntal : 124

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bruntal : Novartis Investigative site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Bruntal : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Bruntal : Site Reference ID/Investigator# 55812

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Bruntal : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Ceska Lipa : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ceske Budejovice : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Chomutov : Site Reference ID/Investigator# 55807

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Hlucin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hlucin : Site Reference ID/Investigator# 55817

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Hradec Kralove : 38

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hradec Kralove : 38

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hradec Kralove : 61

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Hustopece : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Jihlava : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Jihlava : Site Reference ID/Investigator# 55815

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Kladno : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Kromeriz : Site Reference ID/Investigator# 55809

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Liberec : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Mlada Boleslav : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Ostrava : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Ostrava : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Ostrava : Novartis Investigational site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Ostrava : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ostrava : Site Reference ID/Investigator# 55811

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Ostrava - Trebovice : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Ostrava - Trebovice : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Pardubice : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Pardubice : Site Reference ID/Investigator# 55816

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Plzen : 58

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Prague : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Prague : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Praha : 37

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Praha : 37

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Praha : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Praha : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Praha : 49

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Praha 11 :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Praha 2 : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Praha 2 : Karel Pavelka

Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

Praha 4 :

A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate

Praha 4 : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Praha 4 Nusle : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Sokolov : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Terezin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Uherske Hradiste : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Uherske Hradiste : Novartis Investigational site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Uherske Hradiste : Site Reference ID/Investigator# 55814

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Uherske Hradiste : Novartis Investigative Site

Secukinumab Efficacy and Safety Study in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-TNFα Agents.

Uherske Hradiste : 40

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Uherské Hradiste : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Zlin : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Zlin : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Zlin : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Zlin : Novartis Investigative site

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 1 Year of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents

Zlin : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Zlin : Site Reference ID/Investigator# 55806

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Zlin : PV-Medical s.r.o.

Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening

Zlín : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Ålborg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Frederiksberg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Glostrup : Merck Sharp & Dohme

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Hellerup :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Hjorring : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

View More »

Holbæk :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Køge :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis

Kolding :

An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis

Odense :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Silkeborg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Svendborg :

A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment

Cuenca :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Guayaquil :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Quito :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Cairo : Site Ref # / Investigator 75093

Rheumatoid Arthritis Patients on Adalimumab to Evaluate Its Effect on Synovitis Using Ultrasonography in an Egyptian Population

Parnu : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Tallinn : Vertex Investigational Site

24-week Study With Open Label Extension of VX-509, an Oral JAK3 Inhibitor, in Subjects Taking Methotrexate

Tallinn :

A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)

Tallinn : Research Site

A Study of Mavrilimumab in Subjects With Moderate-to-Severe Rheumatoid Arthritis

Tallinn : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

View More »

Tartu :

A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab)

Tartu : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Helsinki :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Helsinki : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Helsinki : Helsinki University Central Hopsital

REstore Working Ability in RheumatoiD Arthritis

Joensuu :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Jyväskylä :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

View More »

Kuopio :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Lahti :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Paimio :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Riihimäki :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Rovaniemi :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Rovaniemi : Lappland Central Hospital

REstore Working Ability in RheumatoiD Arthritis

Tampere :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Tampere : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Tampere : Tampere University hospital, Rheumatology Centre

REstore Working Ability in RheumatoiD Arthritis

Turku : The Turku Universitry Central Hopsital

REstore Working Ability in RheumatoiD Arthritis

Vaasa :

An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab)

Aix Les Bains :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Amiens :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Amiens Cedex : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Angers :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Auch :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

View More »

Aulnay Sous Bois :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bastia :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bayonne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Beauvais :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Belfort :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Belley :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Berck :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Besancon :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bois Guillaume :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bondy :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bonneville :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bordeaux :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Boulogne-billancourt :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bressuire :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Brest :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Bry Sur Marne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Cahors :

A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Cahors :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Cahors Cedex 9 : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Cannes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Carcassonne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Chambray Les Tours :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Chambray Les Tours : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Chateauroux :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Clermont Ferrand : 95

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Clermont Ferrant : 95

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Clermont-Ferrand : Site Reference ID/Investigator# 55511

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Colmar :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Compiegne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Corbeil Essonnes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Corbeil-essonnes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Courbevoie : Laboratoires Merck Sharp & Dohme - Chibret

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 in Participants With Rheumatoid Arthritis (MK-8457-010 AM2)

Creteil :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Denain :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Digne Les Bains :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Dijon :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Dole :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Draguignan :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Dreux :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Dreux : Site Reference ID/Investigator# 55509

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Echirolles :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Epernay :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Evian Les Bains :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Evreux :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Evry :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Frejus :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Freyming-merlebach :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

GAP :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Haguenau :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Ivry Sur Seine :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Laon :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lavaur :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Le Bouscat :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Le Coudray :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Le Kremlin Bicetre :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Le Kremlin Bicetre : 16

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Le Kremlin Bicetre : 16

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Le Mans : 85

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Le Mans : 85

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Le Mans : 70

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Libourne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lievin :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lille :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lille : Site Reference ID/Investigator# 55502

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Limoges :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lomme :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lyon :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Lyon : 62

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Lyon Cedex 3 :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Maisons Laffitte :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Marseille :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Marseille : 48

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Marseille : 48

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Metz Tessy :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Montauban :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Montauban Cedex : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Montpellier :

A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Montpellier : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Montpellier :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Montpellier : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Montpellier Cedex 5 : 88

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Montpellier Cedex 5 : 88

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Montpellier Cedex 5 : 72

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Moulins :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Mulhouse :

A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Mulhouse :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Nanterre :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Nantes : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Nantes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Narbonne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Nevers :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Nice :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Nimes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Orleans :

A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Orleans : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Orleans : 34

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orleans : 34

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Orleans : 90

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Orleans Cedex 1 : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Paris :

A Long-Term Extension Study of WA22763 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis

Paris : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Paris :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Paris Cedex 10 : Site Reference ID/Investigator# 55504

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Paris Cedex 14 : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Perigueux :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Perpignan :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Pierre Benite :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Poissy :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Poitiers : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Poitiers : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Pontoise :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Rennes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Rodez :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Roubaix :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Sainte Maxime :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Salon de Provence :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

St Brieuc :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

St Chamond :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

St Mande :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

St Priest En Jarez :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Strasbourg :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Strasbourg : 79

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Strasbourg : 79

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Suresnes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Thionville : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Thionville :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Toulon :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Toulouse :

A Long-Term Extension Study of WA19926 on the Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis

Toulouse :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Tourcoing :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Tours : For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

A Study in Moderate to Severe Rheumatoid Arthritis

Tours :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Valenciennes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Vandoeuvre les Nancy : Site Reference ID/Investigator# 55496

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Vandoeuvre-les-nancy :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Vannes :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Villeneuve St Georges :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Villeuneuve Sur Lot :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Villeurbanne :

An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice (ACT-SOLO)

Aachen : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Ahlen : Site Reference ID/Investigator# 35510

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ahlen : Site Reference ID/Investigator# 30699

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Ahrensburg : Site Reference ID/Investigator# 35040

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Ahrensburg : Site Reference ID/Investigator# 30726

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

View More »

Altenburg : Site Reference ID/Investigator# 35043

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Altenburg : 17 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Altenburg : Site Reference ID/Investigator# 30727

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Altenholz : Site Reference ID/Investigator# 51043

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Amberg : Site Reference ID/Investigator# 35049

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Amberg : Site Reference ID/Investigator# 30398

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Arnstadt : Site Reference ID/Investigator# 53603

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Attendorn : Site Reference ID/Investigator# 35520

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Auerbach : Site Reference ID/Investigator# 30006

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Augsburg : Site Reference ID/Investigator# 30717

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Abbach : Site Reference ID/Investigator# 33358

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Abbach : Site Reference ID/Investigator# 33361

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Abbach : Site Reference ID/Investigator# 30714

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Aibling : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Aibling :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bad Aibling : Site Reference ID/Investigator# 35142

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Bramstedt : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Bramstedt : Site Reference ID/Investigator# 35573

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Bramstedt : Site Reference ID/Investigator# 49288

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Doberan : 52

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bad Doberan : 52

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bad Doberan : Site Reference ID/Investigator# 53610

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Endbach : Site Reference ID/Investigator# 33372

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Homburg : Site Reference ID/Investigator# 51066

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Iburg : Site Reference ID/Investigator# 33378

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Iburg : Site Reference ID/Investigator# 33382

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Iburg : Site Reference ID/Investigator# 30372

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Iburg : Site Reference ID/Investigator# 30422

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Kreuznach : Site Reference ID/Investigator# 35575

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Kreuznach : Site Reference ID/Investigator# 33387

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Kreuznach : Site Reference ID/Investigator# 30348

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Liebenwerda : Site Reference ID/Investigator# 30705

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Muender : Site Reference ID/Investigator# 33396

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Muender : Site Reference ID/Investigator# 53400

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Nauheim : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bad Nauheim : 23 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Bad Nauheim : Kerckhoff Clinic

Preference Methotrexate (MTX) Pre-filled Syringe Versus Pre-filled Pen in Rheumatoid Arthritis (RA)

Bad Nauheim : Site Reference ID/Investigator# 51073

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Neuenahr :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bad Neuenahr : Site Reference ID/Investigator# 35578

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Neuenahr : Site Reference ID/Investigator# 53611

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Neuenahr : Site Reference ID/Investigator# 53384

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Salzungen : Site Reference ID/Investigator# 51883

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Salzungen : Site Reference ID/Investigator# 75114

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Soden-Salmuenster : Site Reference ID/Investigator# 33412

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bad Staffelstein : Site Reference ID/Investigator# 30334

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Toelz : Site Reference ID/Investigator# 49263

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bad Toelz : Site Reference ID/Investigator# 49261

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Baden-Baden : Site Reference ID/Investigator# 33425

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Baden-Baden : Site Reference ID/Investigator# 30725

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bamberg : Site Reference ID/Investigator# 33429

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bamberg : Site Reference ID/Investigator# 30324

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bautzen : Site Reference ID/Investigator# 30815

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bautzen : Site Reference ID/Investigator# 30330

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bayreuth : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bayreuth :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Bayreuth : Site Reference ID/Investigator# 33442

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bayreuth : Site Reference ID/Investigator# 33446

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bayreuth : 17

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bayreuth : 17

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Bayreuth : 31 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Bayreuth : 33 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Bayreuth : Site Reference ID/Investigator# 30443

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bayreuth : Site Reference ID/Investigator# 30424

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bensheim : Site Reference ID/Investigator# 29883

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Berlin :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Berlin :

An Observational Study on The Safety and Effectiveness of Mabthera (Rituximab) in The First Six Months of Treatment in Patients With Severe Active Rheumatoid Arthritis

Berlin : Study Site (Berlin 1)

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Berlin : Study Site (Berlin 2)

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Berlin : Local Institution

Efficacy and Safety of Abatacept Subcutaneous (SC) in Combination With Methotrexate in Adults With Very Early Rheumatoid Arthritis (RA)

Berlin : Site Reference ID/Investigator# 33648

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33661

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33687

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34246

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33620

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33658

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33670

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33674

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33690

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33697

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 33704

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34269

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 34238

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35527

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35550

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : Site Reference ID/Investigator# 35551

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin : 113

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Berlin : 120

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Berlin : 113

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Berlin : 120

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Berlin : Updated

First Human Dose Trial of NNC0215-0384 in Subjects With Rheumatoid Arthritis

Berlin : 60 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Berlin : 18 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Berlin : 19 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Berlin : 58 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Berlin : 101 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Berlin : Site Reference ID/Investigator# 29866

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30246

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30288

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30290

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30394

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 49253

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 64823

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 53406

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 49313

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 51050

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 53387

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 64826

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30396

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30707

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30462

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30218

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 30234

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 53385

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 51074

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin : Site Reference ID/Investigator# 51108

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin :

Safety and Tolerability of NNC0114-0006 at Increasing Dose Levels in Subjects With Rheumatoid Arthritis

Berlin :

Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis

Berlin : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Berlin : 56

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Berlin-Buch : Site Reference ID/Investigator# 34266

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Berlin-Buch : Site Reference ID/Investigator# 53608

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Berlin-Wannsee : Site Reference ID/Investigator# 53390

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bernau : Site Reference ID/Investigator# 35556

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bernau : Site Reference ID/Investigator# 56686

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Bernau : Site Reference ID/Investigator# 30713

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bietigheim-Bissingen : Site Reference ID/Investigator# 49303

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Blaubeuren : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Blaubeuren : Site Reference ID/Investigator# 56691

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Blaubeuren : Site Reference ID/Investigator# 30817

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bocholt : Site Reference ID/Investigator# 35566

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bocholt : Site Reference ID/Investigator# 34291

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bochum : Site Reference ID/Investigator# 35641

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bochum : Site Reference ID/Investigator# 49287

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bogen : Site Reference ID/Investigator# 35644

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bogen : Site Reference ID/Investigator# 30306

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bonn : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Bonn : Site Reference ID/Investigator# 34296

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 34302

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 35646

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bonn : Site Reference ID/Investigator# 30279

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bonn : Site Reference ID/Investigator# 49302

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bonn : Site Reference ID/Investigator# 53404

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bottrop : Site Reference ID/Investigator# 35652

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Braunschweig : Site Reference ID/Investigator# 49284

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Braunschweig : Site Reference ID/Investigator# 30264

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Breitenbrunn : Site Reference ID/Investigator# 35603

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bremen : Site Reference ID/Investigator# 35609

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Bremen : Site Reference ID/Investigator# 51142

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bremen : Site Reference ID/Investigator# 29875

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Bruchhausen-vilsen : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Burghausen : 21 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Celle : Site Reference ID/Investigator# 35611

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Chemnitz : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Chemnitz : Site Reference ID/Investigator# 35093

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Chemnitz : Site Reference ID/Investigator# 34699

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Chemnitz : Site Reference ID/Investigator# 29807

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Chemnitz : Site Reference ID/Investigator# 30284

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Coesfeld : Site Reference ID/Investigator# 35615

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 33989

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cologne : Site Reference ID/Investigator# 53391

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cologne : Site Reference ID/Investigator# 53409

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cottbus : Site Reference ID/Investigator# 34708

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Cottbus : 75 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Cottbus : Site Reference ID/Investigator# 30812

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Cottbus : Site Reference ID/Investigator# 30344

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Darmstadt : Site Reference ID/Investigator# 30318

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Darmstadt : Site Reference ID/Investigator# 29983

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Deggendorf : Site Reference ID/Investigator# 30382

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dessau-Rosslau : Site Reference ID/Investigator# 35631

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dessau-Rosslau : Site Reference ID/Investigator# 49272

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Donaueschingen : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Dortmund : Site Reference ID/Investigator# 35634

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dortmund : Site Reference ID/Investigator# 34742

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Dresden :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 35170

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34748

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 34754

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Dresden : Site Reference ID/Investigator# 30390

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 30703

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 49244

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 49283

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Dresden : Site Reference ID/Investigator# 30256

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Duesseldorf : Site Reference ID/Investigator# 34768

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Duesseldorf : Site Reference ID/Investigator# 34773

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Duesseldorf : Site Reference ID/Investigator# 56692

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Duesseldorf : Site Reference ID/Investigator# 51107

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Duesseldorf : Site Reference ID/Investigator# 49278

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Duisburg : Site Reference ID/Investigator# 29813

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Eberswalde : Site Reference ID/Investigator# 34784

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Eberswalde : Site Reference ID/Investigator# 49290

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Elmshorn : Site Reference ID/Investigator# 35184

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Elmshorn : Site Reference ID/Investigator# 30298

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Emmerich : Site Reference ID/Investigator# 49258

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Erfurt :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Erfurt : Site Reference ID/Investigator# 35096

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 35191

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erfurt : Site Reference ID/Investigator# 34809

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Erfurt : 89

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Erfurt : 89

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Erfurt : Site Reference ID/Investigator# 30364

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Erfurt : Site Reference ID/Investigator# 30722

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Erlangen :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Erlangen : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Erlangen : Site Reference ID/Investigator# 34821

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Essen : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Essen : Site Reference ID/Investigator# 35196

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 35199

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Essen : Site Reference ID/Investigator# 30740

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Essen : Site Reference ID/Investigator# 49268

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Feldafing : Site Reference ID/Investigator# 75113

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Flensburg : Site Reference ID/Investigator# 35205

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Forchheim : Site Reference ID/Investigator# 34833

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Forchheim : Site Reference ID/Investigator# 30376

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankenberg : Site Reference ID/Investigator# 30252

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankenberg-Sachsen : 8 Updated

Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors

Frankfurt :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Anti-TNFa Biologics

Frankfurt : Study Site

Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)

Frankfurt : Site Reference ID/Investigator# 34840

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankfurt : Site Reference ID/Investigator# 34849

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankfurt : Site Reference ID/Investigator# 34843

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Frankfurt : 70

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Frankfurt : 70

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Frankfurt : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Frankfurt : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Frankfurt : Site Reference ID/Investigator# 30260

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 30248

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 49260

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 49247

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt : Site Reference ID/Investigator# 49286

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Frankfurt Am Main : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Frankfurt am Main : Pfizer Investigational Site

Study Comparing Doses Of An Experimental Glucocorticoid Compound To Prednisone And Placebo In Rheumatoid Arthritis

Fraureuth : Site Reference ID/Investigator# 35213

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiberg : Site Reference ID/Investigator# 35219

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiberg : Site Reference ID/Investigator# 30366

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freiburg : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Freiburg : Site Reference ID/Investigator# 34854

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Freiburg : Investigative Site

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

Freiburg : Site Reference ID/Investigator# 49294

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freiburg : Site Reference ID/Investigator# 51099

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Freiburg : Site Reference ID/Investigator# 29810

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Friedrichroda : Site Reference ID/Investigator# 51047

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Fulda :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Fulda : 47

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Geesthacht : Site Reference ID/Investigator# 49307

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Gera : Site Reference ID/Investigator# 34883

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Giessen : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Giessen : Site Reference ID/Investigator# 34887

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Giessen : Site Reference ID/Investigator# 51055

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Gladbeck : Site Reference ID/Investigator# 49273

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Gommern : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Gosheim : Site Reference ID/Investigator# 35491

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Goslar : Site Reference ID/Investigator# 34896

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Goslar : 28

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Goslar : 28

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Goslar : Site Reference ID/Investigator# 56891

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Göttingen : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Greifswald : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Greifswald : Site Reference ID/Investigator# 49259

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Greifswald : Site Reference ID/Investigator# 49256

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Greifswald : Site Reference ID/Investigator# 30328

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Guben : Site Reference ID/Investigator# 35498

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Guestrow : Site Reference ID/Investigator# 34912

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Guestrow : Site Reference ID/Investigator# 30404

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hagen : Site Reference ID/Investigator# 35503

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hagen : Site Reference ID/Investigator# 75116

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Haldensleben : Site Reference ID/Investigator# 56688

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Halle : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Halle : Site Reference ID/Investigator# 34932

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34944

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34937

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Site Reference ID/Investigator# 34940

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Halle : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Halle : Site Reference ID/Investigator# 56687

Observational Study to Research the Effectiveness of Adalimumab Treatment in Conjunction With Utilization of a Patient Support Program (PSP)

Halle : Site Reference ID/Investigator# 30452

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Halle : Site Reference ID/Investigator# 30729

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Updated

A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis

Hamburg :

A Trial of NNC0109-0012, an Anti-IL-20 Biologic, in Patients With Active Rheumatoid Arthritis Who Are Inadequate Responders to Methotrexate

Hamburg :

An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 34958

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34970

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34994

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35449

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 34961

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35000

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35111

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35444

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : Site Reference ID/Investigator# 35452

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hamburg : 71

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hamburg : 71

Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Hamburg : Research Site

Evaluation of Efficacy and Safety of Fostamatinib Monotherapy Compared With Adalimumab Monotherapy in Patients With Rheumatoid Arthritis (RA)

Hamburg : Research Site

Evaluation of Long-term Safety and Effectiveness of Fostamatinib in the Treatment of Rheumatoid Arthritis (RA)

Hamburg : Site Reference ID/Investigator# 30797

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30818

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30821

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49245

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49312

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49295

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 49280

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30716

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 29833

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30286

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30292

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30340

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30346

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30702

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30739

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30400

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30715

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : Site Reference ID/Investigator# 30392

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hamburg : 17

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Hanau : Site Reference ID/Investigator# 35019

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hanau : Site Reference ID/Investigator# 30270

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hannover : Site Reference ID/Investigator# 30029

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hanover : Site Reference ID/Investigator# 33712

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hanover : Site Reference ID/Investigator# 35025

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Hanover : Site Reference ID/Investigator# 30262

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Hanover : Site Reference ID/Investigator# 53393

Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis

Harrislee : Site Reference ID/Investigator# 33792

Efficacy and Safety of Adalimumab in Patients With Rheumatoid Arthritis in Routine Clinical Practice

Heidelberg : Updated